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Abstract 
Background: The receptor for activated C kinase 1 (RACK1) is involved in various cancers, but its roles in nasopharyn‑
geal carcinoma (NPC) have not yet been fully elucidated.
Methods: Initially, RACK1 expression was analyzed by immunohistochemistry in NPC and normal nasopharyngeal 
(NP) tissues. It was also detected by qPCR and Western blot in NPC cells. Confocal microscope and immunofluores‑
cence were performed to detect the subcellular compartmentalization of RACK1. Subsequently, after up‑ or down‑
regulating RACK1 in NPC cells, cell proliferation and migration/invasion were tested using in vitro assays including 
MTT, EdU, colony formation, Transwell and Boyden assays. Furthermore, several key molecules were detected by West‑
ern blot to explore underlying mechanism. Finally, clinical samples were analyzed to confirm the relationship between 
RACK1 expression and clinical features.
Results: Receptor for activated C kinase 1 expression was much higher in NPC than NP tissues. And RACK1 was 
mainly located in the cytoplasm. Overexpression of RACK1 promoted NPC cell proliferation and metastasis/invasion, 
whereas depletion of this protein suppressed NPC cell proliferation and metastasis/invasion. Mechanistically, RACK1 
deprivation obviously suppressed the activation of Akt and FAK, suggesting the PI3K/Akt/FAK pathway as one of func‑
tional mechanisms of RACK1 in NPC. Furthermore, clinical sample analysis indicated a positive correlation between 
in vivo expression of RACK1 with lymph node invasion and clinical stage of NPC.
Conclusion: Our results demonstrate that RACK1 protein plays an important role in NPC development and progres‑
sion. The upregulation of RACK1 can promote the proliferation and invasion of NPC by regulating the PI3K/Akt/FAK 
signal pathway. Thus, this study contributes to the discovery of a potential therapeutic target for NPC.
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Background
Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nancy with high incidence rate in Chinese and other 
Southeast Asians. Most NPC patients cannot be timely 
diagnosed in early stage due to non-specific symptoms 
and deep location of lateral nasopharyngeal recess [1, 2]. 
Although chemoradiation therapy has recently improved 
the 5  year survival rate of NPC patients, clinical NPC 
prognosis is generally poor due to recurrence and metas-
tasis [3]. Therefore, it is urgent to discover valuable novel 
biomarkers for NPC early diagnosis, prognostic evalua-
tion, and molecularly targeted therapy.
Receptor for activated protein kinase C (RACK1) is an 
adaptor protein with seven WD40 motifs, 36 kDa, mainly 
allocated in cytosol and cytoplasmic membrane, provid-
ing a scaffold for multiple protein–protein interactions, 
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regulate many cellular actions including cell growth, dif-
ferentiation, adhesion, migration and immunity [4–8]. 
Recently, researchers have found the high expression of 
RACK1 in a multitude of tumors such as melanomas, 
breast cancer, colorectal cancer, pulmonary adenocarci-
noma, hepatoma, esophageal squamous cell carcinoma, 
and oral squamous cell carcinomas. With regard to its 
roles in tumorigenesis, RACK1 mainly contributes to 
tumor growth, invasion and metastasis [9–15]. How-
ever, some contradictory results exist in its oncogenic 
property; this protein can exert a negative control on Src 
activity [16] and an inhibitory effect on Ki-Ras-mediated 
morphological cell transformation [17]. It is also reported 
to be down-regulated in gastric cancer, acting as a tumor 
suppressor negatively regulating the Wnt signaling [18]. 
Interestingly, more and more studies indicated RACK1 
is interacted with some proteins (such as, ZEBRA, LMP1 
and A73) encoded by Epstein–Barr virus (EBV) which 
has been implicated in the molecular abnormalities lead-
ing to NPC [19–22], implying that RACK1 probably 
impacts N NPC development and progression. Therefore, 
the roles of RACK1 in NPC are deserved to be explored.
In the present study, we have examined the mRNA and 
protein expression levels of RACK1 in NPC cell lines and 
tissue samples, explored the in vitro effects of RACK1 on 
cell proliferation and invasion/metastasis, disclosed the 
underlying molecular mechanism, and further evaluated 
the clinical relevance of RACK1 to NPC. This is the first 
to investigate the roles of RACK1 in NPC.
Methods
Tissue samples collection
NPC samples and non-cancerous nasopharyngeal sam-
ples (NP) were collected from the First Affiliated Hospi-
tal of Southern Medical University, Nanfang Hospital of 
Guangzhou City, China between January 2012 and July 
2014. All tissue specimens were obtained at the time of 
nasal endoscopy diagnosis before any anti-tumor therapy. 
All biopsy samples had been confirmed by pathologi-
cal diagnosis. TNM staging was performed according to 
the 7th Edition of the AJCC/UICC Cancer Staging Man-
ual (The 2009 NPC staging system of the WHO). Prior 
consents were obtained from the patients before using 
these clinical materials for research. The study was also 
approved by the Ethics Committee of Nanfang hospi-
tal. Each tissue was fixed in buffered formalin for 48  h, 
embedded in paraffin and sectioned, stored at 4 °C before 
immunohistochemical staining.
Immunohistochemistry
Paraffin sections (5 μm) from samples of 58 NPC and 37 
nasopharyngeal specimens were deparaffinized in 100 % 
xylene and re-hydrated in descending ethanol series (100, 
90, 80, 70  % ethanol) and water according to standard 
protocols. Heat-induced antigen retrieval was performed 
in 10  mM citrate buffer for 2  min at 100  °C. Endog-
enous peroxidase activity and non-specific antigen were 
blocked with 3 % hydrogen peroxide and serum, followed 
by incubation with mouse anti-human RACK1 antibody 
(1:500 dilution, BD Biosciences, SanJose, CA, USA) for 
overnight at 4 °C. After washing, the sections were incu-
bated with biotin-labeled anti-mouse IgM antibody (Bos-
der Inc, Wuhan, China) for 30 min at room temperature, 
and subsequently were incubated with SABC (Bosder 
Inc, Wuhan, China) for 30 min at room temperature. The 
peroxidase reaction was developed using 3, 3-diamin-
obenzidine chromogen solution in DAB buffer substrate. 
Sections were visualized with DAB and counterstained 
with hematoxylin, mounted in neutral gum, and analyzed 
using a bright field microscope. All sections were scored 
by two independent pathologists, and the staining index 
was calculated as the product of the staining intensity 
(1, no staining; 2, weak staining; 3, moderate staining; 4, 
strong staining) and the proportion of positive cells (1, 
<10 %; 2, 10–35 %; 3, 35–70 %; 4, >70 %).
Cell culture
All cells were graces from Cancer Research Institute of 
Southern Medical University. Human NPC cell lines 
(5–8F, CNE-1, CNE-2, 6–10B, SUNE-1, and HONE1) 
were cultured in RPMI-1640 (HyClone) medium sup-
plemented with 10  % fetal bovine serum (Gibco). The 
immortalized nasopharyngeal epithelial cell line NP69 
was grown in keratinocyte/serum-free medium (Invitro-
gen) supplemented with bovine pituitary extract. Cells 
were incubated at 37 °C in a humidified incubator of 5 % 
CO2.
RNA extraction, cDNA synthesis and quantitative PCR
Total RNA was extracted using TRIzol reagent (Invit-
rogen) according to the manufacturer’s instructions. 
1  μg total RNA was reverse-transcibed to Single-strand 
cDNA using primeScript® RT reagent kit (TaKaRa, 
Dalian, China) according to the manufacturer’s instruc-
tions. Real-time PCR was performed using SYBR Premix 
Ex Taq (TaKaRa, Dalian, China) with an Mx3005P real-
time PCR system (Stratagene, La Jolla, CA, USA). The 
following primers were used for RACK1: 5′-AGCAG-
CAACCCTATCATCGTC-3′ (forward) and 5′-TGAGA-
TCCCATAACATGGCCT-3′ (reverse). Human GAPDH 
was used as the normalization control, primers for 
GAPDH were as follows: 5′-CATGGGTGTGAACCAT-
GAGA-3′ (forward) and 5′-GTCTTCTGGGTGGCAGT-
GAT-3′ (reverse). Reactions containing no template or 
primer were used as negative controls. Temperature 
cycling parameters for RACK1 and GAPDH were with an 
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initial denaturing at 95 °C for 30 s, 45 cycles of denatur-
ing at 95 °C for 10 s, and annealing at 60 °C for 20 s. The 
relative expression levels were calculated by the 2-ΔΔCT 
Method.
Western blot analysis
Cells were lysed by RIPA buffer (Fdbio science Inc, Hang-
zhou, China) with protease inhibitor (Fdbio science Inc, 
China) and phosphatase inhibitor (KeyGEN, Nanjing, 
Jiangsu, China) on ice for 30 min. The protein concentra-
tions were determined by the BCA method (KeyGEN, 
Nanjing, Jiangsu, China). Protein was diluted by sample 
loading buffer (4:1) and boiled at 95 °C for 5 min. 30 μg of 
total proteins per lane were subjected to electrophoresis 
on a 12 % SDS-PAGE gel and transferred to PVDF mem-
branes (Millipore, Billerica, MA, USA). The membranes 
were blocked with TBST containing 5 % BSA for 1 h fol-
lowed by overnight incubation at 4  °C with the primary 
antibodies for RACK1 (1:5000 dilution, BD Biosciences, 
SanJose, CA, USA), GAPDH (1:2000 dilution, Bioworld 
Technology, MN,US), phosphor-Akt (Ser473) and Akt 
(1:1000 dilution, Cell Signaling Technology, MA, USA), 
anti-FAK (phosphor Y397) and FAK (1:1000 dilution, 
Abcam, Cambridge, UK) respectively. After washing with 
TBST, the membranes were incubated with the second-
ary antibody goat anti mouse IgM (1:5000 dilution, Bos-
der Inc, Wuhan, China) or goat anti-mouse IgG or goat 
anti- rabbit IgG (1:5000 dilution, Bosder inc, China) for 
1 h at room temperature. The signals were visualized by 
an enhanced chemiluminescence Western blot kit (Milli-
pore, USA), quantified by ChemiDocTM CRS Molecular 
Imager (Bio-Rad, Amersham, USA). Protein was normal-
ized with GAPDH.
Confocal Microscope
Paraffin section (5 μm) were prepared as the above immu-
nohistochemistry procedure, after blocked with 10  % 
normal goat serum for 30  min at room temperature, the 
sections were incubated with mouse anti-human RACK1 
antibody (1:200 dilution, BD Biosciences, SanJose, CA, 
USA) and rabbit anti-human claudin-1 antibody (1:200 
dilution, Thermo Fisher, USA) together for overnight at 
4 °C. After washing, The secondary antibody DyLight 488 
goat anti-mouse IgG (1:200 dilution, Abbkine, CA, USA) 
and DyLight 594 goat anti-rabbit IgG (1:200 dilution, 
Abbkine, CA, USA) were used together for 1  h at room 
temperature, DAPI was used to stain the cell nuclei at a 
concentration of 1 µg/ml. The sections were mounted using 
anti-fade mounting medium. Images were captured at 
600× magnification with OLYMPUS Confocal Laser Scan-
ning Microscope, and analysed with FV10-ASW1.7 viewer 
software (Olympus America Inc., USA). Investigated wave-
length: 473 nm (green); red (559 nm); 405 nm (blue).
Immunofluorescence assays
Cells were cultured on coverslips overnight (70 % conflu-
ence), fixed with 4 % formaldehyde in PBS for 15 min at 
room temperature, and then permeabilized with 0.5  % 
Triton-X-100 in PBS for 10 min. Subsequently, cells were 
blocked for nonspecific binding with 10  % normal goat 
serum in PBS at RT for 30 min, incubated with RACK1-
specific antibody (1:500 dilution, BD Biosciences, USA) 
at 4 °C overnight. The cells were incubated with DyLight 
488 goat anti-mouse IgG (1:100 dilution, Abbkine, CA, 
USA) at 37  °C for 1 h. The coverslips were mounted on 
slides using anti-fade mounting medium with DAPI. 
Immunofluorescence images were acquired on Nikon 
ECLIP SE 80i microscope (Nikon, Tokyo, Japan). The 
excitation/emission wavelengths: green/EX: 450–490 nm, 
EM: 520 nm; blue/EX: 340–380 nm, EM:435–485 nm.
Plasmids and small interfering RNA transfection
GFP-RACK1 and GFP-vector were purchased from 
Addgene Corporation, America. The following siRNAs 
designed based on the human RACK1 cDNA (Gen-
BankTM accession number GNB2L1) were synthe-
sized by Ribo bioscience Inc, Guangzhou, China. The 
sequences of RACK1 siRNA are si1, CAGGGATGAGA-
CCAACTAT and si2, CAAACACCTTTACACGCTA. 
After optimization experiments regarding to the si-RNA 
concentrations, NPC cells were transfected with 100 nM 
RACK1 siRNAs or 100 nM negative control siRNA using 
the Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s directions. All Western blot and func-
tional studies were carried out in 48 h after transfection.
Cell proliferation assay
Cell proliferation was assessed using MTT kit. The cells 
were seeded on 96-well microplates at a density of 3000 
cells per well. At 1–3  days, the cells were incubated 
with 20  μl of MTT labeling reagent (0.5  mg/ml, Sigma-
Aldrich) for 4  h, followed by the addition of 100  μl of 
dimethylsulfoxide (Sigma-Aldrich) into each well. The 
plates were kept in darkroom for 15 min and OD value 
was measured with BioTek ELx800 microplate photome-
ter (BioTek ELx800, SN 21 18 05, US). Investigated wave-
length: 570 nm, reference wavelength: 690 nm.
Colony formation assay
5–8F and CNE1 cells were transfected with GFP-RACK1 
plasmid or control plasmid/siRNA targeting RACK1 or 
unspecific srambled siRNA respectively for 24  h, and 
then seeded in six-well plates at a density of 500 cells 
per well. After cultured for 7 or 12  days, colonies were 
fixed with 4  % paraformaldehyde solution, stained with 
hematoxylin, and counted under an inverted microscope 
(Nikon, Tokyo, Japan).
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5‑Ethynyl‑2′‑deoxyuridine (EdU) incorporation assay
Cells were incubated with EdU (final concentration, 
10  μM) for 2  h and analyzed using a Click-iT® EdU 
Alexa Fluor® Imaging Kit (Ribo bioscience Inc, Guang-
zhou, China) according to the manufacturer’s instruc-
tions. Images were captured using a Nikon ECLIP SE 80i 
microscope (Nikon, Tokyo, Japan) and the percentage of 
EdU-positive cells was measured.
Migration and invasion assay
Cell migration assay was carried out using a transwell 
chamber (8  µm pore size; Corning, NY, USA). For cell 
invasion assay, polycarbonate membrane filters of tran-
swell chamber need coated with Matrigel (BD Bio-
sciences, Bedford, MA, USA). Briefly, the cells were 
trypsinized and suspended at a final concentration of 106 
cells/ml in serum-free media. The cell suspension (100 µl) 
was loaded into the upper wells and 10  %FBS contain-
ing media was used as a chemotatic factors in the lower 
wells. The plate was incubated at 37 °C for 16–20 h. After 
removing the cells remaining in the upper chamber, the 
cells migrated through the membrane were fixed in etha-
nol and stained using hematoxylin or Giemsa stain, and 
then photographed using an inverted microscope (Nikon, 
Tokyo, Japan). The number of migrating or invading cells 
was quantified by counting the cells in five random high-
power fields and calculating the mean number of cells. 
All assays were repeated independently at least for three 
times.
Statistical analysis
All statistical analyses were performed with SPSS 20.0 
software. Student T test was performed for two groups. 
One-way ANOVA and Dunnett’s multiple comparison 
test was used for multiple groups. Two-way ANOVA test 
was conducted to analysis two factors data. All date are 
presented as the mean ± sem for at least three independ-
ent experiments. P Values were two-sided and less than 
0.05 were considered statistically significant.
Results
The RACK1 expression in NPC cells and clinical tissues
To evaluate the roles of RACK1 in NPC, we initially 
detected the protein expression level of RACK1 in 58 
paraffin-embedded NPC samples and 37 non-cancerous 
nasopharyngeal (NP) samples using immunohistochemi-
cal staining. Figure  1a–d showed the representative 
images of RACK1 expression in NPC and NP tissues. 
RACK1 protein was detectable in 98  % (57/58) of NPC 
samples and in 86  % (32/37) of NP samples. Notably, 
RACK1 protein expression was considerably higher in 
NPC samples than NP samples (P < 0.001) (Fig. 1e). 76 % 
(44/58) of NPC samples showed high expression level of 
RACK1, while only 30 % (11/37) of NP samples showed a 
relatively high expression level of RACK1. We then per-
formed IF staining to define the subcellular localization 
of RACK1 protein in NPC tissues. Tight junction pro-
tein claudin-1 was used as a cell membrane marker (red), 
nuclei were stained with DAPI (blue). Confocal micros-
copy examinations showed that the positive staining of 
RACK1 (green) was observed in the cytoplasm (Addi-
tional file  1: Figure S1). These data imply that RACK1 
probably plays its roles in NPC through protein–protein 
interaction in the cytoplasm. Moreover, we investigated 
RACK1 expression in NPC cell lines and immortal-
ized nasopharyngeal epithelial cell NP69. The results 
showed compared to NP69, the level of RACK1 mRNA 
was not significantly increased in NPC cells, even a little 
decreased in some NPC cells (Fig.  1f ). But highly inva-
sive NPC cells (5-8F, CNE2) showed higher expression 
levels of RACK1 protein than relatively low malignant 
NPC cells (SUNE1, 6–10B) and NP69 (Fig. 1g, h). Immu-
nofluorescence images showed the similar localization of 
RACK1 in NPC cells to tissue samples Additional file 1: 
Figure S1). These results collectively suggest that RACK1 
is associated with NPC progression.
The effect of RACK1 on NPC proliferation
To investigate the effect of RACK1 on NPC tumorigen-
esis and progression, two NPC cells (5–8F and CNE1) 
were selected to be transfected with RACK1 or con-
trol plasmid. The specific RACK1 plasmid with a GFP 
tag, expressing a 65  kDa GFP-RACK1 fusion protein 
(Additional file  2: Figure S2), was used to indicate the 
overexpression level of exogenous RACK1 because 
endogenous RACK1 had already expressed in these 
NPC cells (Fig.  2a). Green fluorescence displayed that 
RACK1 protein was also more specifically localized in 
the cytoplasm of RACK1-transfected cells than control 
cells (Additional file  2: Figure S2). After plasmid trans-
fection, MTT assays, colony formation assays and EdU 
assays were carried out to determine the effect of RACK1 
on cell viability and proliferation ability. Overexpressed 
RACK1 appeared to increase cell growth (Fig.  2b), the 
percentage of EdU-positive cell (Fig.  2c, d), and colony 
formation (Fig.  2e, f ) of NPC cells compared with con-
trol cells. Although the influence of RACK1 overexpres-
sion on NPC cell growth is not obvious, it has a statistical 
significance. Maybe as the native expression of RACK1 
in NPC cell is enough, so that the results of overexpres-
sion of RACK1 are not so obvious. Subsequently, NPC 
cells (5–8F and CNE1) were transfected with si-RACK1 
or scrambled siRNA to knock down RACK1. Relative to 
scrambled control siRNA, RACK1 protein expression 
was obviously inhibited in 5–8F and CNE1 cells treated 
with RACK1-siRNA (Fig. 3a). Notably, after transfection 
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with si-RACK1, 5–8F and CNE1 cells displayed cell 
growth inhibition (Fig. 3b), the percentage of EdU posi-
tive cells reduced (Fig. 3c, d) as well as fewer and smaller 
colonies (Fig.  3e, f ) compared with scrambled control. 
Taken together, these data indicate the promotion of cell 
proliferation by RACK1 in NPC.
Fig. 1 The expression of RACK1 in NPC tissues and cells. a–d The expression of RACK1 was evaluated by immunohistochemistry in NPC and NP 
tissues. Original magnification, ×400; scale bar 25 μm. e The histogram shows the difference of RACK1 expression (IHC score) in NPC tissues and 
NP tissues. Student’s t test. f The relative expression levels of RACK1 mRNA in NPC cells and NP69 determined by qRT‑PCR, quantified by relating 
to GAPDH. One‑way ANOVA and Dunnett’s multiple comparison tests. g, h RACK1 protein expressions in NPC cells and NP69 were measured by 
Western blot. One‑way ANOVA and Dunnett’s multiple comparison test. Mean ± sem, N = 3, *P < 0.01, **P < 0.01, ***P < 0.001
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The effect of RACK1 on NPC migration and invasion
Furthermore, the effect of RACK1 on NPC cell migra-
tion and invasion was determined using Transwell assays 
and Boyden assays. First, western blots were conducted 
to test the successfully overexpression or knockdown of 
RACK1 in NPC cells (Fig. 4a, b). As shown in (Fig. 4c), 
overexpressed RACK1 stimulated cell migration in NPC 
cells (5–8F and CNE1). The cell invasion abilities were 
also significantly increased as assessed using modified 
Boyden assays (Fig. 4d). Next, the migration and invasion 
phenotypes were compared between NPC cells treated 
with si-RACK1 and control cells. Similarly, down-regu-
lation of RACK1 inhibited the migration and invasion of 
NPC cells (5–8F and CNE1) (Fig. 4e, f ). Thus, these data 
demonstrate that RACK1 also enhances NPC cell migra-
tion and invasion.
Fig. 2 RACK1 propels NPC cells proliferation. a 5–8F and CNE1 NPC cells were transfected with GFP‑RACK1 plasmid or control plasmid, and then 
analyzed by western blot. GAPDH served as the internal control. b MTT assays were conducted to detect the cell growth in indicated NPC cells. 
Two‑way ANOVA test. c, d The cell proliferation status in NPC cells was also tested by EdU assay. Original magnification, ×100; scale bar 100 μm. Stu‑
dent’s t‑test. e, f Besides, the clone formation ability of NPC cells was compared after transfected with RACK1 plasmid or control plasmid. Student’s 
t‑test. Mean ± sem, N = 3, *P < 0.05, **P < 0.01, ***P < 0.001
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The mechanism underlying RACK1’s functions in NPC
It is in NPC carcinogenesis that PI3K/Akt signal pathway 
has been proved to be highly implicated. Several studies 
have reported that RACK1 can regulate the activation 
of PI3K/Akt and FAK [23–30]. To determine the possi-
ble mechanism involved in the regulation of cell prolif-
eration and migration/invasion by RACK1, we analyzed 
the protein levels of p-Akt(S473)/Akt and p-FAK(Y397)/
FAK by western blot after overexpression or knockdown 
of RACK1 in NPC cells. The in vitro results revealed that 
RACK1 was able to activate Akt and FAK (Fig. 5a–c) and 
the endogenous p-Akt (S473) and p-FAK (Y397) levels 
were remarkably reduced in RACK1 deprived NPC cells 
(Fig. 5d–f). In addition, p-Akt (S473) and p-FAK (Y397) 
levels were restored upon the re-expression of RACK1 
(Additional file  2: Figure S2). These data suggest that 
the PI3K/Akt/FAK pathway may be one of the regula-
tory mechanisms involved in RACK1’s functions in NPC. 
Epithelial-mesenchymal transition (EMT) is closely 
implicated in carcinogenesis, so the expression status of 
some EMT associated genes (vimentin, E-cadherin and 
N-cadherin) was also detected after RACK1 overexpres-
sion or deprivation. However, no significant changes 
Fig. 3 Down‑regulated RACK1 attenuates cells proliferation. a After NPC cells transfected with RACK1 siRNA or si‑control, the expression of RACK1 
was detected by western blot. b MTT assay was applied to measure the cell growth. Two‑way ANOVA test. c, d Beside, EdU assay was used to test 
the proliferation of NPC cells. Original magnification, ×100; scale bar 100 μm. Student’s t‑test. e, f Plate clone formation assay also showed the differ‑
ence of NPC cells proliferation. The data were shown as the mean ± sem Student’s t‑test. *P < 0.05, **P < 0.01, ***P < 0.001
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were observed (Additional file  2: Figure S2), suggesting 
RACK1 may not participate in EMT in NPC.
Relationship between RACK1 expression 
and clinicopathological variables in NPC patients
To further support our above findings, 58 NPC patients 
were recruited for in  vivo evaluating the correlation 
between RACK1 protein expression level and clinico-
pathologic features. We did not find a significant asso-
ciation of RACK1 expression with patients’ age, sex, and 
tumor size, but we observed significant correlations of 
RACK1 expression with lymph node invasion and clinical 
stage (Table 1). These data provide further evidence that 
RACK1, correlating with advanced NPC, plays an impor-
tant role in NPC progression.
Discussion
A large number of studies reveal that RACK1 is associ-
ated with various signaling molecules involving the reg-
ulation of various cellular functions [4, 6–8]. Aberrant 
expression of RACK1 has been reported in numerous 
cancers [9–13]—particularly several squamous cell car-
cinomas such as esophageal squamous cell carcinoma 
(ESCC), oral squamous cell carcinoma (OSCC) and 
gastric cancer [14, 15, 18]. To our knowledge, the roles 
of RACK1 expression in NPC carcinogenesis and pro-
gression have rarely been reported. In the present study, 
using Western blotting and immunohistochemical analy-
ses, we first found that RACK1 protein was expressed at 
a relatively higher level in NPC samples. As a scaffolding 
protein, RACK1 has been found to be more likely to bind 
Fig. 4 The effect of RACK1 on NPC cell migration and invasion. a, b western blots showed the successfully overexpression or knockdown of RACK1 
in NPC cells. The migration and invasion of NPC cells were tested by Transwell (c) and Boyden assays (d) respectively after NPC cells were transfected 
with RACK1 or control plasmid. In addition, after NPC cells were treated by si‑RACK1 or si‑control, Transwell (e) and Boyden assays (f) were also per‑
formed to detect the migration and invasion ability of NPC cells. Original magnification, ×200; scale bar 50 μm. Student’s t‑test, mean ± sem, N = 3. 
*P < 0.05, **P < 0.01, ***P < 0.001
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to various signaling proteins in cytoplasm and several cell 
surface receptors [4, 8]. Interestingly, our results also dis-
played a specific localization of RACK1 in the cytoplasm 
in NPC tissues and cells. This suggests that RACK1 plays 
roles in NPC through regulating some pathways that 
require interaction of multiple proteins in the cytoplasm.
There is an interesting fact in our research; the mRNA 
expression level of RACK1 in NPC cells was not signifi-
cantly higher than that of NP69, even in some NPC cells 
RACK1 mRNA expression level was lower than NP69. 
This is similar to some previous studies on the roles of 
RACK1 in breast cancer [10, 11] and thyroid cancer 
[31]. These studies also obtained inconsistent results; 
the mRNA expression level of RACK1 in tumor tis-
sues was lower than normal tissues, whereas the protein 
expression level of RACK1 in tumor tissues was signifi-
cantly higher than normal tissues. This implies the exist-
ence of a complicated post-transcriptional regulation of 
RACK1. As we know, post-transcriptional regulation is 
an important regulatory mechanism in nasopharyngeal 
carcinoma. Besides, although NP69 is an immortalized 
nasopharyngeal epithelial cell, it is a relatively normal 
cell line compared with tumor cell, so maybe it can not 
fully reflect the physiological characteristics of RACK1 
expression in normal nasopharyngeal epithelial tissues.
Discovery of more reliable molecular biomarkers is 
meaningful for NPC management. Researchers have 
made considerable achievements in recent years. Some 
valuable biomarkers such as VEGF protein, IL-8 recep-
tor A [32], Bmi-1 [32, 33], etc. have been found to be 
associated with the development and poor prognosis 
of NPC. Some important molecules such as Tiam1 [32, 
33], TSLC1 [34], FGFR4 [35], FLOT1 [36] and CCL2-
CCR2 axis [37], etc. are closely correlated the metasta-
sis, invasion and EMT of NPC. Moreover, HOTAIR, a 
cancer-related long non-coding RNA is discovered to be 
up-regulated in NPC and associated with poor prognosis 
as well [38]. However, it is in NPC that there has been no 
Fig. 5 The expression of key members of PI3 K/Akt pathway in NPC cells. a Western blot showed the expression levels of p‑Akt(S473)/Akt and 
p‑FAK(Y397)/FAK in NPC cells transducted by GFP‑RACK1 plasmid or GFP‑Tag control plasmid. d The expression of p‑Akt(S473)/Akt and p‑FAK(Y397)/
FAK in 5–8F and CNE1 cells was measured by western blot after transfected with RACK1 siRNA or unspecific scrambled siRNA. GAPDH served 
as the internal control. b, c, e, f Densitometry quantifications were performed for three independent experiments. The data were shown as the 
mean ± sem Student’s t‑test, (*P < 0.05, **P < 0.01)
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report of the roles of RACK1, though RACK1 has been 
demonstrated to be a potential prognostic indicator in 
multiple cancers including breast cancer [10, 11, 39] 
and pulmonary adenocarcinomas [12, 40] and so on. In 
the present study, we found that RACK1 contributed to 
NPC cell proliferation and invasion. Silencing of RACK1 
expression suppressed NPC cell proliferation and migra-
tion. RACK1 expression was significantly associated with 
lymph node invasion and clinical stage in NPC patients. 
Our observations first indicate that RACK1 can pro-
mote the NPC development and progression, suggesting 
RACK1 as a potential prognostic biomarker or therapeu-
tic target for clinical applications.
It is well established that RACK1 promotes cell prolif-
eration and invasion via its interactions with diverse part-
ners or through various signaling pathways. RACK1 can 
enhance cell growth by activating Sonic hedgehog (SHH) 
signaling in NSCLC [41] and MKK7/JNK activity in HCC 
[42]. It can increase THP1 proliferation through activat-
ing GSK3β activity in acute myeloid leukemia cells [43]. 
It is worth noting that RACK1 has recently emerged as an 
essential molecule for FAK’s function as it interacts with 
FAK to form complex and regulates FAK activity. Phos-
phorylation of RACK1 on Tyr-52 by c-Abl mediates the 
interaction with FAK [23–25, 44]. Suppression of RACK1 
expression can disrupt FAK activity and reduce cell migra-
tion. Besides, RACK1 can modulate PI3K/Akt signaling 
or activates Akt to propel cell proliferation and invasion/
metastasis in VEGF/Flt1-mediated endothelial cells [26], 
mouse hepatocarcinoma cells [27], renal cell carcinoma 
[28], and some other cancers [29, 30]. In the present study, 
our results also revealed that RACK1 activated Akt and 
FAK in NPC. To our knowledge, PTEN is a crucial fac-
tor regulating PI3K/Akt and activating FAK. Its expres-
sion can be down-regulated by either CpG methylation at 
its promoter [45] or EBV-encoded miRNAs [46] in NPC. 
Interestingly, Gunaratne et al.’s [46] data show that RACK1 
can combine with PTEN, so it is possible that RACK1 may 
affect cell growth and metastasis/invasion of NPC through 
PTEN/PI3K/Akt and FAK pathway, which we are planning 
to fully validate in the following studies. In addition, it has 
been reported that RACK1 may play a role in the virus 
infection and immune system. EBV encoded proteins A73, 
BZLF1 and ZEBRA can interact with RACK1 [19–22]. 
This provides clues that the interaction between RACK1 
and EBV-associated immunity may be one of the mecha-
nisms underlying NPC development and progression.
Conclusion
The present study demonstrated that high expression 
of RACK1 was closely associated with cell proliferation 
and metastasis/invasion in NPC. Regulation of the PI3K/
Akt/FAK pathway was one of functional mechanisms 
of RACK1 in NPC. Our findings are useful for further 
understanding of RACK1-based molecular mechanisms 
underlying NPC progression and providing a potential 
prognostic biomarker or therapeutic target.
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